Aarti Drugs Limited
All news and filings related to Aarti Drugs Limited.
View all news & filings- Medium impact
Aarti Drugs: Prakash M. Patil steps down as MD & CEO; Adhish P. Patil promoted to MD
Aarti Drugs announces management changes. Prakash M. Patil has resigned as Chairman, MD & CEO effective September 30, 2026. Adhish P. Patil has been promoted to Managing Director from October 1, 2026, and relinquishes his CFO role. A new CFO will be appointed.
Read the summary - Low impact
Aarti Drugs: Trading Window Closed from Oct 1, 2026 for Q2 FY27 Results
Aarti Drugs Limited will close its trading window from October 1, 2026. The window will reopen 48 hours after the announcement of financial results for the quarter and half-year ended September 30, 2026.
Read the summary - Medium impact
Aarti Drugs Appoints Nilesh Patil as Whole-Time Director, Adhish Patil as MD
Aarti Drugs Limited's AGM on September 26, 2026, approved management changes. Nilesh Bhalchandra Patil appointed Whole-time Director from Sep 26, 2026. Adhish Prakash Patil appointed Managing Director from Oct 1, 2026. Several re-appointments for directors and independent directors were also approved.
Read the summary - Medium impact
Aarti Drugs Limited's 41st AGM: All resolutions passed with high majority
Aarti Drugs Limited's 41st AGM on September 26, 2026, saw all resolutions pass with high majorities. Key decisions included adopting financial statements and approving director appointments and re-appointments. The company also approved its 'Aarti Drugs Limited Performance Stock Option Plan 2026'.
Read the summary - Low impact
Aarti Drugs holds 41st AGM on Sep 26, 2026, presents FY26 business overview
Aarti Drugs held its 41st AGM on Sep 26, 2026, presenting its FY26 business overview. Consolidated revenue reached ₹2,568 Cr, with PAT at ₹312 Cr. The company highlighted growth strategies including a ₹200 Cr oncology investment and ₹600 Cr capex. ESG and CSR initiatives were also detailed, with ₹414.26 Lakhs invested in FY26.
Read the summary - Medium impact
Aarti Drugs Ltd Holds 41st AGM, Approves Financials and Director Appointments
Aarti Drugs Limited conducted its 41st AGM on Sep 26, 2026. The company approved its audited financials for FY26 and appointed/re-appointed several directors, including a new MD. The PSOP 2026 plan was introduced for employees. Voting results are expected within two working days.
Read the summary - Low impact
Aarti Drugs Announces 41st AGM on Sep 26, 2026, via VC/OAVM
Aarti Drugs Limited has completed the dispatch of its Annual Report for FY25-26. The 41st Annual General Meeting (AGM) is scheduled for September 26, 2026, at 11:00 AM IST, to be held via Video Conference. The announcement was published on September 3, 2026.
Read the summary - Low impact
Aarti Drugs submits Business Responsibility and Sustainability Report for FY25-26
Aarti Drugs submitted its FY25-26 Business Responsibility and Sustainability Report. The report details ESG initiatives, including 10 ZLD facilities, climate change mitigation, and sustainable sourcing. R&D and capex investments for environmental and social impact were 27% and 15% respectively in FY25-26. The company also provides details on corporate governance and stakeholder engagement.
Read the summary - Low impact
Aarti Drugs announces 41st AGM on Sep 26, 2026, to be held via VC/OAVM
Aarti Drugs Limited will hold its 41st Annual General Meeting on September 26, 2026. The meeting will be conducted via Video Conferencing/Other Audio Visual Means. The Annual Report for FY 2025-26 and the AGM notice have been shared with shareholders.
Read the summary - Low impact
Aarti Drugs Ltd. Announces 41st AGM on Sep 26, 2026
Aarti Drugs Limited will hold its 41st Annual General Meeting on September 26, 2026, at 11:00 AM IST. The meeting will be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
Read the summary - Low impact
Aarti Drugs Approves Performance Stock Option Plan 2026
Aarti Drugs Limited's Board approved the Performance Stock Option Plan 2026. The plan allows for granting up to 8 lakh stock options convertible into equity shares. This is subject to member approval and complies with SEBI regulations.
Read the summary - Low impact
Aarti Drugs Board Meeting on Aug 27 to Consider ESOP Plan 2026
Aarti Drugs board meeting scheduled for August 27, 2026, to consider the Performance Stock Option Plan 2026. Trading window to remain closed from August 25 to August 29, 2026.
Read the summary - Low impact
Aarti Drugs Schedules Investor Meetings on August 20, 2026
Aarti Drugs Limited will hold investor meetings on August 20, 2026, in Mumbai. Officials will meet with analysts and institutional investors in 1x1/Group meetings organized by Systematix. Discussions will be limited to publicly available information.
Read the summary - Medium impact
Aarti Drugs: Supreme Court dismisses GST Dept's plea against company
Aarti Drugs Limited announced the Supreme Court dismissed the GST Department's Special Leave Petition. The litigation involved a demand of ₹230.70 Crores for FY18-22. The Supreme Court's decision favors the company, with no expected financial or operational impact.
Read the summary - Medium impact
Aarti Drugs Q1 FY27 Earnings Call Transcript Released
Aarti Drugs reported Q1 FY27 consolidated revenue of ₹703.6 crore, up 19% YoY. EBITDA grew 30% to ₹96.9 crore with a 13.8% margin. Standalone revenue increased 20% to ₹627.6 crore. The company is expanding its Sayakha and Baddi facilities and targeting 10-15% volume growth over the next two years.
Read the summary - Low impact
Aarti Drugs to Meet Investors on August 10, 2026
Aarti Drugs Limited will hold an investor meeting on August 10, 2026, from 11 AM to 1 PM. The meeting, organized by Nirmal Bang, will take place at Trident BKC, Mumbai. Discussions will be limited to publicly available information.
Read the summary - Low impact
Aarti Drugs: Audio Recording of Q1 FY27 Investor Call Uploaded
Aarti Drugs Limited has uploaded the audio recording of its investor conference call for the quarter ended June 30, 2026. The transcript will be shared shortly. The call discussed the company's financial results.
Read the summary - Low impact
Aarti Drugs Publishes Q1 FY27 Financial Results in Newspapers
Aarti Drugs Limited published its standalone and consolidated financial results for the quarter ended June 30, 2026. The results were published in Financial Express and Pratahkal on August 2, 2026, in compliance with SEBI regulations.
Read the summary - Medium impact
Aarti Drugs Q1 FY27: Revenue Up 19%, EBITDA Soars 30% YoY
Aarti Drugs reported Q1 FY27 consolidated revenue of ₹703.6 crore, up 19% YoY. EBITDA increased 30% to ₹96.9 crore with margins at 13.8%. PBT grew 35% YoY to ₹69.2 crore. The company highlighted strong operational performance, improved realisations, and capacity expansion plans.
Read the summary - Medium impact
Aarti Drugs Q1 FY27 Revenue Jumps 19% YoY to ₹703.6 Crore, PAT at ₹50.1 Crore
Aarti Drugs reported Q1 FY27 consolidated revenue of ₹703.6 crore, up 19% YoY. EBITDA grew 30% YoY to ₹96.9 crore, with margins expanding by 120 bps. PAT was ₹50.1 crore. Specialty Chemicals revenue surged 150% YoY. The company is expanding OSD capabilities and expects improved operating leverage.
Read the summary - Low impact
Aarti Drugs' Sayakha Plant Operations Resumed; GPCB Levies ₹10.2 Lakhs Compensation
Aarti Drugs' Sayakha plant operations will continue after GPCB revoked closure directions. The company has paid an interim Environmental Damage Compensation of ₹10.2 Lakhs. No financial or operational impact is expected.
Read the summary - Medium impact
Aarti Drugs Announces Leadership Transition: Rashesh Gogri to Chairman, Adhish Patil as MD
Aarti Drugs Limited announced leadership changes effective October 1, 2026. Rashesh C. Gogri will become Chairman and continue as MD. Adhish P. Patil is appointed as the new MD. Prakash M. Patil will retire from executive roles on September 30, 2026.
Read the summary - Medium impact
Aarti Drugs Appoints Rashesh Gogri as Chairman, Adhish Patil as MD
Aarti Drugs announced leadership changes: Chairman, MD & CEO Prakash M. Patil retires Sep 30, 2026. Rashesh C. Gogri becomes Chairman from Oct 1, 2026. Adhish P. Patil appointed MD for 5 years from Oct 1, 2026. Several other director re-appointments and committee reconstitutions were also approved.
Read the summary - Medium impact
Aarti Drugs Q1 FY27 Profit Declines to ₹48.64 Cr, Revenue at ₹702.78 Cr
Aarti Drugs reported consolidated profit after tax of ₹48.64 crore for the quarter ended June 30, 2026, down from ₹50.17 crore in the prior quarter. Consolidated total income was ₹720.30 crore, a slight decrease from ₹725.90 crore.
Read the summary - Low impact
Aarti Drugs Schedules Q1 FY27 Earnings Conference Call for August 3rd
Aarti Drugs Limited will host its Q1 FY27 earnings conference call on Monday, August 3, 2026, at 11:00 AM IST. Investors and analysts will discuss financial performance for the quarter ended June 30, 2026. Key management personnel will be present.
Read the summary - Medium impact
Aarti Drugs Plant Closure Directed by GPCB, Operations to Cease in 15 Days
Aarti Drugs Limited received a closure direction from Gujarat Pollution Control Board for its Bharuch plant, effective 15 days from July 18, 2026. The closure is due to non-compliance with Water Act and CCA conditions. The company is taking corrective measures and expects no immediate financial impact.
Read the summary - Low impact
Aarti Drugs Promoter Group Members Encumber Shares
Harshit Manilal Savla, Promoter of Aarti Drugs, declared that Mirik Rajendra Gogri encumbered 6,41,814 shares and Renil Rajendra Gogri encumbered 5,97,957 shares as of March 31, 2026. This falls under SEBI Takeover Regulations.
Read the summary - Low impact
Aarti Drugs to hold Group Meeting with Investors on June 23, 2026
Aarti Drugs Limited will conduct a group meeting with investors on June 23, 2026, from 10:00 AM to 3:30 PM in Tarapur, Maharashtra. Discussions will be limited to publicly available information, with no UPSI to be shared.
Read the summary - Low impact
Aarti Drugs Ltd. Publishes Notice on Transfer of Equity Shares to IEPF Account
Aarti Drugs Limited published a notice on June 16, 2026, regarding the transfer of equity shares to the Investor Education and Protection Fund (IEPF) Account. This is in compliance with the Companies Act, 2013 and IEPF Rules. The notice appeared in Financial Express and Pratahkal.
Read the summary - Medium impact
Aarti Drugs Q4 FY26 Earnings Call Transcript Released
Aarti Drugs released its Q4 FY26 earnings call transcript. Q4 FY26 revenue was ₹721.1 Cr (up 6% YoY), EBITDA ₹96.6 Cr (up 72% QoQ), and PAT ₹55.3 Cr (up 36% QoQ). Formulations revenue grew 41% YoY to ₹91.3 Cr. The company is ramping up its methylamine plant and targeting 8-10% volume growth with FY27 EBITDA margins of 13.5-14%. Capex of ₹300-400 Cr planned over 2-3 years.
Read the summary - Low impact
Aarti Drugs to Meet Investors on May 27, 2026, Organized by 360 ONE Capital
Aarti Drugs Limited officials will meet investors on May 27, 2026, from 10 AM to 1 PM. The meeting, organized by 360 ONE Capital, will be held at Grand Hyatt, Mumbai. Discussions will be limited to publicly available information.
Read the summary - Low impact
Aarti Drugs: Audio Recording of Q4FY26 Investor Call Uploaded
Aarti Drugs Limited has uploaded the audio recording of its investor conference call for the quarter and year ended March 31, 2026. The transcript will be available on the company website soon. The call was initially intimated on May 12, 2026.
Read the summary - Low impact
Aarti Drugs Publishes Standalone & Consolidated Financial Results for Q4FY26
Aarti Drugs Limited published its standalone and consolidated financial results for the quarter and year ended March 31, 2026. The results were announced on May 17, 2026, in compliance with SEBI regulations.
Read the summary - Medium impact
Aarti Drugs Q4 & FY26 Investor Presentation: Revenue Up 6% YoY to ₹721 Cr
Aarti Drugs reported Q4 FY26 revenue of ₹721.1 crore, up 6% YoY. FY26 revenue reached ₹2,565.3 crore, a 7% increase. PAT for FY26 grew 16% to ₹194.9 crore. The company saw strong sequential recovery in Q4 with revenue up 20% and EBITDA up 72%. Focus on regulated markets and exports continues.
Read the summary - Medium impact
Aarti Drugs Q4 FY26 Revenue Up 6% YoY to ₹721 Crore, PAT Declines 12%
Aarti Drugs reported Q4 FY26 consolidated revenue of ₹721.1 crore, up 6% YoY. PAT declined 12% YoY to ₹55.3 crore but grew 36% QoQ. For FY26, revenue was ₹2,567.7 crore (up 7% YoY) and PAT was ₹194.9 crore (up 16% YoY). Formulations and Specialty Chemicals segments showed strong growth.
Read the summary - Medium impact
Aarti Drugs Board Approves Q4 FY26 Results, Reappoints Auditors & Risk Committee Member
Aarti Drugs Limited approved its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reappointed M/s GMVP & Associates LLP as Cost Auditor and M/s Raman S. Shah & Co. as Internal Auditor. The Risk Management Committee was also reconstituted.
Read the summary - Low impact
Aarti Drugs Approves FY26 Audited Results & Reappoints Cost & Internal Auditors
Aarti Drugs Limited's Board approved audited standalone and consolidated financial results for FY26. They re-appointed M/s GMVP & Associates LLP as Cost Auditor for FY27 and M/s Raman S. Shah & Co. as Internal Auditor for three years from April 1, 2026. The Risk Management Committee was also reconstituted.
Read the summary - Low impact
Aarti Drugs Schedules Q4 & FY26 Earnings Conference Call for May 18
Aarti Drugs Limited will host an investor and analyst conference call on May 18, 2026, at 11:00 AM IST. The call will discuss the company's financial performance for the quarter ended March 31, 2026. Key management will participate.
Read the summary - Low impact
Aarti Drugs Announces Special Window for Physical Share Re-lodgement
Aarti Drugs Limited announced a special window for re-lodging physical share transfer requests. The notice was published on April 8, 2026, in Financial Express and Pratahkal, adhering to SEBI regulations.
Read the summary - Low impact
Aarti Drugs Announces Publication of Investor Awareness Campaign 'Saksham Niveshak'
Aarti Drugs Limited has published advertisements for the 'Saksham Niveshak' investor awareness campaign by the IEPF, MCA. The ads appeared on April 7, 2026, in Financial Express (English) and Pratahkal (Marathi). This is a continuation of an earlier intimation.
Read the summary - Low impact
Aarti Drugs Ltd. Files SEBI Certificate for Q4 FY26 Dematerialization
Aarti Drugs Limited submitted a certificate for the quarter ended March 31, 2026, confirming dematerialization of securities as per SEBI regulations. The Registrar and Transfer Agent processed and confirmed the securities received from depository participants.
Read the summary - Low impact
Aarti Drugs Launches 'Saksham Niveshak' Campaign for Unclaimed Dividends
Aarti Drugs relaunches the 'Saksham Niveshak' campaign from April 1 to July 9, 2026. This initiative encourages shareholders to update KYC details and claim unpaid/unclaimed dividends before they are transferred to the IEPF. Shareholders can submit required documents via post, email, or online.
Read the summary - Low impact
Aarti Drugs: Trading Window Closed from April 1 for Q4FY26 Results
Aarti Drugs Limited will close its trading window starting April 1, 2026. The window will reopen 48 hours after the announcement of the financial results for the quarter and year ending March 31, 2026.
Read the summary - Medium impact
Aarti Drugs Limited: ICRA Reaffirms Credit Ratings
ICRA Limited has reaffirmed Aarti Drugs Limited's credit ratings. Long-term facilities totaling ₹367.80 crore received an '[ICRA] AA- (Stable)' rating. Short-term facilities of ₹1,085.00 crore were reaffirmed with an '[ICRA] A1+' rating. The total rated amount stands at ₹1,452.80 crore.
Read the summary - Medium impact
Aarti Drugs: GST Dept Challenges Bombay HC Order, Files SLP in Supreme Court
Aarti Drugs' GST litigation continues as the GST Department files a Special Leave Petition in the Supreme Court challenging the Bombay High Court's order. The dispute involves a potential demand of ₹230.70 Crores related to IGST refunds, interest, and penalties. The company is defending its position, and the financial impact is currently unclear.
Read the summary - Medium impact
Aarti Drugs Invests ₹10 Crore in Wholly Owned Subsidiary Pinnacle Life Science
Aarti Drugs will invest ₹10 crore in its wholly owned subsidiary, Pinnacle Life Science, via a Rights Issue. The funds will support Pinnacle's expansion and capex plans. Pinnacle Life Science reported a turnover of ₹25,392.38 lakhs for FY25. Shares will be allotted by March 20, 2026.
Read the summary - Low impact
Aarti Drugs to attend Investec Investors Conference on 11 March 2026
Aarti Drugs will attend the Investec Investors Conference in Mumbai on March 11, 2026, from 10:00 AM to 2:00 PM. The discussions will be based on publicly available information, with no unpublished price-sensitive information to be disclosed. This event includes 1x1 and group meetings.
Read the summary - Low impact
Aarti Drugs Subsidiary Tripharma Chile SpA Incorporated in Chile
Aarti Drugs Limited's subsidiary, Pinnacle Chile SpA, has incorporated a new wholly-owned step-down subsidiary, Tripharma Chile SpA, in Chile. The incorporation was processed on February 27, 2026. The new entity will focus on marketing formulation drugs in Chile.
Read the summary - Low impact
Aarti Drugs Cancels Analyst/Institutional Investor Meeting Scheduled for Feb 18
Aarti Drugs Limited has cancelled its Analyst/Institutional Investor Meeting scheduled for February 18, 2026. The meeting was organized by Dolat Capital and was planned as a 1x1/Group Meeting.
Read the summary - Medium impact
Aarti Drugs Q3 FY26 Earnings Call Transcript Released
Aarti Drugs released its Q3 FY26 earnings call transcript. Consolidated revenue grew 8% YoY to ₹602.9 Cr. PAT surged 58% YoY to ₹40.5 Cr. The company saw 7% volume growth in standalone business and expects improved performance due to capacity ramp-up and focus on formulations and exports.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio